

Triennial Report

(including 2024 Annual Activity Statement)

Queensland Cancer Control Safety and Quality Partnership
2022-2024



Contents

Introduction.....	3
Functions.....	4
Summary of the activities performed, and outcomes achieved.....	5
Quality Assurance Committee membership.....	11
Current members details	12
Privacy policy.....	19
Meeting dates	25
Appendices.....	26

Introduction

The Queensland Cancer Control Safety and Quality Partnership (The Partnership) was established in October 2004 with a single goal; *clinician-led service improvement*. The Partnership aims to achieve this by providing the cancer community with the systems and tools to routinely review, share and compare data on cancer treatment and outcomes. Involving cancer clinicians in deciding how to achieve the best possible cancer outcomes is our priority. The Partnership is a gazetted quality assurance committee under Part 6, Division 1 of the Hospital and Health Boards Act 2011.

There are 15 subcommittees established as part of the Partnership which cover the following cancers, treatment modalities and specialty groups.

Brain	Gynaecological	Hepatobiliary	Non-melanoma skin	Sarcoma
Breast	Haematology	Lung	Paediatric	Systemic Therapy
Colorectal	Head and Neck	Melanoma	Radiation Oncology	Youth cancer

Functions

To collect and compile data on clinical care, processes and outcomes.

To feedback data to receivers, administrators and providers of cancer services (public and private) to enable the evaluation, management, monitoring or planning of cancer services.

To undertake safety and quality related health services and clinical research.

To disseminate information on the safety and quality of cancer services in Queensland through research publications, conferences and other cancer related professional development and training activities.

To establish sub-committees to consider and make recommendations to the Partnership on specific cancer related research, safety and quality issues as required.

To provide governance and guidelines for undertaking review of proposals to determine whether a proposal is a quality assurance activity (which is exempt from requiring Human Research Ethics Committee (HREC) review) or is a research project.

To ensure the timely reporting of safety and quality issues.

To provide clinicians with data, systems and tools to enable the collection of clinical data relevant to the evaluation, management, monitoring or planning of cancer services, clinician participation in safety and quality activities and the delivery of quality cancer care.

To report and make recommendations regarding cancer related safety and quality issues.

To work with the receivers of and public and private providers of cancer services and relevant professional groups to identify and negotiate the implementation of local and statewide solutions to the identified safety and quality gaps.

Make recommendations to the Minister for Health on standards, guidelines and quality indicators of cancer care.

To monitor the effect of recommendations on the safety and quality of cancer services across Queensland.

Summary of the activities performed, and outcomes achieved

Date	Summary / Learning Outcomes	Implementation status / lead agency
2023 - onwards	Development of a key performance indicator for Breast cancer in Qld by examining the effects of treatment delay on overall and breast cancer specific survival. Breast cancer cohort (Stage I -III) – diagnosed between 2005-2015 and received surgery, chemotherapy and radiation therapy within 18months of diagnosis. Established treatment threshold of 37 weeks to complete treatment. Time from surgery to start of chemotherapy was associated with poorer 5 year survival. Proposal of KPI for the management of early-stage breast cancer: Facilities should aim for >90% of patients with a time from surgery to adjuvant chemotherapy of <6.9 weeks. Reference: https://cancerallianceqld.health.qld.gov.au/media/2033/development-of-a-key-performance-indicator-for-breast-cancer-in-in-queensland-australia.pdf	Completed Breast Cancer subcommittee
2022 - onwards	Sharing of MDT data Multidisciplinary care and formal multidisciplinary team (MDT) review is considered best practice in the treatment planning and care for people diagnosed with cancer. Evidence suggests that people with cancer managed by an MDT are more likely to receive guideline concordant care and have better outcomes. Recommendation: all public and private hospitals commit to sharing multidisciplinary team (MDT) review data to the Queensland Oncology Repository (QOR) enabling state-wide reporting of MDT review rates. Reference: Multiple Cancer Alliance Queensland reports - https://cancerallianceqld.health.qld.gov.au/	Ongoing The Partnership

Date	Summary / Learning Outcomes	Implementation status / lead agency
2022 - onwards	Timely treatment Optimal care pathways provide recommendations on the optimal timeframes for the initiation of treatment after specialist referral. Recommendations are provided for each stage of the treatment pathway to ensure treatment delays do not impact on the Quality of Life (QOL) and psychological distress of people with cancer, and disease progression and survival. Unwarranted variation in time to treatment occur if people are treated in public facilities. Recommendation: Timely treatment for all - reduction in inequities in time to initiation of treatment. Reference: Multiple Cancer Alliance Queensland reports - https://cancerallianceqld.health.qld.gov.au/	Ongoing The Partnership
2023-ongoing	LUCAP – Australian Lung Cancer Clinical Quality Data Platform Establish a National lung cancer data platform to measure outcomes against key clinical quality indicators to identify where improvements can be made to deliver consistent, evidence-based care in Australia There are 3 Lung MDTs in Qld participating in prospective data collection: The Prince Charles Hospital, Royal Brisbane and Women's Hospital and Sunshine Coast University Hospital Baseline report for Qld Non-small Cell Lung Cancer Quality Index 2012-2021 published in August 2024 to provide baseline outcomes for reportable clinical indicators included in the study. Indicators in this national dataset have been incorporated into the Qld QOOL MDT dashboard to allow monitoring at a local level. Reference: https://cancerallianceqld.health.qld.gov.au/reports/lung20122022website-lungreport20122021/#tab1	Ongoing PI – Prof Fraser Brims, Curtin University WA

Date	Summary / Learning Outcomes	Implementation status / lead agency
2024	CanCo - First Nations Cancer Cohort Study Establish a prospective population-based cohort of Qld First Nations peoples diagnosed with cancer and their caregivers to: • Map the cancer care pathways for First Nations people from pre-diagnosis to treatment and beyond • Create a mechanism to routinely code additional data like cancer stage • Investigate the impact of chronic diseases on the diagnosis, treatment and outcomes of cancer • Evaluate the efficacy, cost and financial impact of different treatment approaches. Baseline report Cancer Insights: A Focus on Queensland's Aboriginal and Torres Strait Islander Communities 2012-2021 published in June 2024. Development of database for data collection in testing phase Participant recruitment to commence in 2026	Commenced PI – Prof Gail Garvey, UQ

Date	Summary / Learning Outcomes	Implementation status / lead agency
2024	Project: EGFR mutation testing trend for metastatic, non-squamous non-small cell lung cancer public patients in Qld from 2014-2021 Supervised by the Lung cancer subcommittee and conducted by Dr Zane Young Aim: to examine the rates and trends of EGFR testing over time, since the test was approved for public funding in August 2013. Outcomes: • EGFR mutation testing rates and turnaround time has significantly improved between 2014-2021 • 12.6% of patients were found to have an EGFR mutation • Significantly more rural patients (21.1%) lack conclusive EGFR results compared with urban patients (15.1%). Overall EGFR no result rates (16.1%) and mean result time (24.2 days), may indicate an ongoing need for improvement in the Qld public health diagnostic testing.	Completed Cancer Alliance Queensland, MSHHS Gold Coast University Hospital Sunshine Coast University Hospital
2024	Project: The impact of rurality and socioeconomic status on chemotherapy treatment and outcomes for unresectable pancreatic adenocarcinoma. Chemotherapy regimes: Folfirinox (FFX); Gemcitabine + nab-paclitaxel (GP); Gemcitabine only (Gem) Outcomes: • No significant difference in survival based on rurality. • Rural patients more likely to receive Gem. • No difference in chemotherapy regimen or survival based on socioeconomic status. • FFX had better median survival (13mths) compared with GP/Gem (both 9mths). • Less delay to starting chemotherapy for affluent patients. • Private patients more likely to receive FFX, commence chemotherapy sooner and have a slightly longer median OS (12mths vs 10mths).	Completed Cancer Alliance Queensland, MSHHS

Date	Summary / Learning Outcomes	Implementation status / lead agency
2024	Cancer Alliance Queensland's 20th anniversary On 27th June 2024 we celebrated our 20th Anniversary, taking the opportunity to reflect on our progress and achievements, and looking to the future. The Partnership was key to this celebration. Claire Howlett from Cancer Australia attended to discuss the National Cancer Plan and this was followed by the launch of the first report for Qld - Cancer Insights: A focus on Queensland's Aboriginal and Torres Strait Islander Communities. https://cancerallianceqld.health.qld.gov.au/articles/20th-anniversary/ https://cancerallianceqld.health.qld.gov.au/media/zx0boluj/cancer-insights-a-focus-on-queensland-s-aboriginal-and-torres-strait-islander-communities-2012-2021-1st-edition.pdf	Cancer Alliance Queensland, MSHHS

Date	Summary / Learning Outcomes	Implementation status / lead agency
2022-2024	Key Presentations The Partnership's program of work is show-cased through multiple conferences, seminars and presentations both locally and nationally. Highlights include: 2022 - Clinical Oncology Society of Australia (COSA) symposia where the value of linked data in measuring cancer care improvements for Queenslanders were presented including presentations on population cancer data, optimal care pathways, development of a key performance indicator for breast cancer and palliative radiation therapy and the therapeutic landscape for non-metastatic lung cancer. 2023 - Clinical Oncology Society of Australia (COSA) symposia where the Partnership presented information on gynaecological cancer and covered patterns of care in Queensland, equity for first nations women, trends in brachytherapy utilisation and the increased trends in endometrial cancer rates. 2024 - Clinical Oncology Society of Australia (COSA) symposia where lung, pancreatic, merkel cell and brain cancer population data were presented. 2024 – Australian Comprehensive Cancer Network Innovations Showcase hosted by Cancer Australia. Launched the Treating people with cancer in Queensland and Victoria: National Benchmarking starts here – 2017-2021. 2024 – CE Forum and Road Show to discuss the latest report - Treating the 6 most common cancers in Queensland – A report for Hospital and Health Services – 2017-2021.	
2022-2024	Publications – see appendix	

Quality Assurance Committee membership

Queensland Cancer Control Safety and Quality Partnership

Name	Work location (e.g., HHS or town)	Position on sub-committee (i.e. Chair, member, secretariat)	Date membership ceased (if applicable)
Professor Euan Walpole	MSHHS	Chair – 2023, Member – 2017, Chair - 2005	
Professor Mark Smithers AM	MSHHS, University of Qld	Member – Nov 2011	
A/Professor David Wyld	MNHHS	Member – Feb 2016	
Dr Penny Mackenzie	MNHHS	Member – March 2020	
Dr Rick Walker	CHQ	Member – March 2020	
Professor David Clark	MNHHS	Member – July 2024	
Dr Gerry Adams	GenesisCare Bundaberg	Member – July 2024	
Professor Victoria Atkinson	MSHHS, Greenslopes Hospital	Member – July 2024	
A/Professor Bryan Chan	SCUHHS	Member – July 2024	
A/Professor Melissa Eastgate	MNHHS	Member – July 2024	
Dr Ian Irving	ICON Group	Member – July 2024	
Dr Shaun McGrath	MNHHS	Member – July 2024	
Kate McLean	MSHHS	Member – July 2024	
Dancia Cossio	CAQ, MSHHS	Member – July 2024	
Emma Capaldi	CAQ, MSHHS	Secretariat	
Professor David E Theile AO	CAQ, MSHHS, Previous Chair of Partnership	Chair – 2017, Member - 2023	Jan 2025
Professor Joanne Aitken	Cancer Council Queensland	Member – May 2005	Jan 2024
Aniko Cooper	THHS	Member – Feb 2016	Jan 2024
Dr Shoni Philpot	CAQ, MSHHS	Member – Nov 2014	June 2024
A/Professor Peter Steadman	CHQHHS, MSHHS	Member – March 2020	Jan 2024
A/Professor Lindy Jeffree	MNHHS	Member – March 2020	Dec 2023
Bethany Crowe	MSHHS	Member – March 2020	Jan 2024
A/Professor Glen Kennedy	MNHHS	Member – March 2020	Jan 2024
Dr Hazel Harden	Consumer	Member – Feb 2019	Jan 2025

Current members details

Queensland Cancer Control Safety and Quality Partnership

Full name	Date commenced	Qualifications	Position of employment	Summary of experience relevant to QAC	Work location (eg. HHS or town)
Professor Euan Walpole	2005	MBBS, FRACP	Medical Director Cancer Services, PAH and MSHHS	Chair – The Partnership Cancer Alliance Qld Medical Director, Division of Cancer Services Consultant (Medical oncologist) Professor, UQ School of Medicine Honorary Ass of NHMRC Clinical Trials Centre, university of Sydney Acting Chairman Qld Cancer Fund Medical & Scientific Advisory Committee Previous Chairman, Medical Oncology Group of Australia (MOGA) Member, Advisory Committee on Medicines, TGA Recipient Cancer Achievement Award, MOGA 2022 Multiple clinical trials, published journal articles, conference presentations ORCID Id: 0000-0001-6105-9039	MSHHS

<i>Full name</i>	<i>Date commenced</i>	<i>Qualifications</i>	<i>Position of employment</i>	<i>Summary of experience relevant to QAC</i>	<i>Work location (eg. HHS or town)</i>
Dr Ian Irving	2024	MBBS, FRACP, FRCPA, AFRACMA, GAICD	Chief Medical Officer - Icon Group Executive Director - Icon Group Haematologist - Icon Wesley - The Wesley Hospital	Currently a practising clinician, as a Haematologist at Icon Wesley/The Wesley Hospital, Icon Group's Chief Medical Officer and an Executive Director of Icon Group Previously Senior Staff Specialist, Director of Haematology and BMT and Clinical Director of Cancer Services at Townsville University Hospital (in total 2003 – 2017) Previous employment as Haematologist at RBWH (2001), SNP (2001), St James' and St Vincents Hospitals (2002) Supervision, teaching and mentorship of medical students, basic trainees and haematology registrars including being the recipient of the HSAZ award for mentorship (2024). Member of the National Examining Panel of Royal Australasian College of Physicians (2015 – ongoing) Member of RACP, RCPA, AMA, HSAZ, EHA, ASH, ALLG, AAN, THANZ and ANZTCT. Past member of Qld Cancer Care Network, QH High Cost Drugs Committee. Published multiple journal articles, given conference presentations and have acted as a reviewer for journals including Pathology, Internal Medicine Journal and Blood Reviews.	Icon Group, Brisbane

<i>Full name</i>	<i>Date commenced</i>	<i>Qualifications</i>	<i>Position of employment</i>	<i>Summary of experience relevant to QAC</i>	<i>Work location (eg. HHS or town)</i>
Professor Mark Smithers AM	Member – Nov 2011	MBBS, FRACS, FRCSEng, FRSEd (Hon)	Surgical Lead, Queensland Clinical Cancer Network Honorary Consultant, Upper GI Soft Tissue Unit, Princess Alexandra Hospital	Member of the Order of Australia (AM). Emeritus Professor of Surgery, UQ. Honorary Associate, NH&MRC Trials Centre, Faculty of Medicine, University of Sydney. Honorary Professor, Mater Research Institute, UQ. Senior Visiting Medical Officer – General Surgeon, Director, Upper GI and Soft tissue Unit, PAH. Surgical Lead, Qld Clinical Cancer Network Clinical Fellow, Berghofer, QIMR. Chair, Queensland Melanoma Project Past President Australian and Aotearoa New Zealand Gastro-Oesophageal Surgeons Association (AANZGOSA) Multiple research grants, more than 260 published journal articles, multiple conference presentations. ORCID Id 0000-0002-8333-8685. Major focus on cancer treatment	MSHHS
Dr Penny Mackenzie	2020	FRANZCR, Bachelor of Medicine, Bachelor of Surgery (Hons)	Director Radiation Oncology, RBWH	Director of Radiation Oncology RBWH PhD candidate– Geriatric oncology and radiotherapy utilisation with Liverpool Hospital/CCORE and UNSW Fellow of RANZCR Senior Lecturer, UQ Multiple clinical trials, published journal articles, conference presentations	MNHHS

<i>Full name</i>	<i>Date commenced</i>	<i>Qualifications</i>	<i>Position of employment</i>	<i>Summary of experience relevant to QAC</i>	<i>Work location (eg. HHS or town)</i>
Dr Rick Walker	2020	FRACP, MBBS, Grad Dip Sc Genetics, B.Med.Sc	Lead Clinician of QYCS, Qld Children's Hospital/PAH	Paediatric and AYA Oncologist and Medical Director of Qld Youth Cancer Service Member, Paediatric subcommittee Member, Sarcoma subcommittee Multiple clinical trials, published journal articles, conference presentations ORCID Id 0000-0002-2118-8386	MSHHS, QCH
Professor David Clark	2024	FRACS, FRCSEd, PhD, FCSSANZ	Colorectal Surgeon, RBWH/TPCH	Professor UQ Senior Consultant Colorectal Surgeon, RBWH Senior VMO, TPCH Chair, CRC subcommittee Multiple clinical trials, published journal articles, conference presentations ORCID Id 0000-0002-2065-3012	MNHHS
Dr Gerry Adams	2024	FRANZCR, FRCR, MRCPUK, MB ChB	Radiation Oncologist, GenesisCare Bundaberg	Former Dean of Faculty of Radiation Oncology (RANZCR) Former Member of FRO Council Former Chair of Radiation Oncology Alliance Former Chair of Economics and Workforce Committee Multiple clinical trials, published journal articles, conference presentations	GenesisCare Bundaberg

<i>Full name</i>	<i>Date commenced</i>	<i>Qualifications</i>	<i>Position of employment</i>	<i>Summary of experience relevant to QAC</i>	<i>Work location (eg. HHS or town)</i>
A/Prof David Wyld		MBBS, FRACP	Director, Medical Oncology	Director of Medical Oncology Consultant (Medical oncologist) Affiliate QIMR Berghofer Medical Research Institute Member Executive Committee, Statewide Cancer Clinical Network (SCaCN) Co-Chair, SCaCN Drugs and Therapeutics Subcommittee Member, Central Integrated Regional Cancer Service Executive Committee Multiple book chapters, clinical trials, published journal articles, conference presentations	MNHHS
Professor Victoria Atkinson	2024	MBBS, FRACP	Medical Oncologist, PAH, Greenslopes	Fellowship Royal Australasian College of Physicians 2006 (Medical Oncology) Appointed Professor Faculty of Medicine University of Queensland December 2022 Clinical Director Medical Oncology Princess Alexandra Hospital Multiple clinical trials, published journal articles, conference presentations	MSHHS

<i>Full name</i>	<i>Date commenced</i>	<i>Qualifications</i>	<i>Position of employment</i>	<i>Summary of experience relevant to QAC</i>	<i>Work location (eg. HHS or town)</i>
Associate Professor Bryan Chan	2024	BPharm (Hons 1), MBBS (Hons 1, Uni Medal), FRACP, MMed (Clin Epi)	Medical Oncologist, SCUH	Medical Oncologist Representative, Clinical Oncology Society of Australia, Membership Committee. Clinical Oncology Society of Australia, Lung Cancer Chair. Neuroendocrine neoplasms guidelines. Thoracic Oncology and Oncology Research Lead, Sunshine Coast University Hospital, Queensland, Australia Multiple clinical trials, published journal articles, conference presentations	SCHHS
Associate Professor Melissa Eastgate	2024	MBBS, FRACP	Executive Director, Cancer care RBWH	Executive Director, Cancer Care Stream, Metro North HHS Deputy Director, Medical Oncology Associate Professor, University of Queensland MOGA Chair Multiple clinical trials, published journal articles, conference presentations	MNHHS
Dr Shaun McGrath	2024	MBBS, FRANZCOG, CGO	Staff Specialist, Gynaecological Oncology and Gynaecology RBWH and STARS	Staff Specialist, Gynaecological Oncology and Gynaecology. Senior Lecturer, University of Queensland Member – Gynaecology subcommittee Multiple conference presentations, publications and service improvement projects	MNHHS

<i>Full name</i>	<i>Date commenced</i>	<i>Qualifications</i>	<i>Position of employment</i>	<i>Summary of experience relevant to QAC</i>	<i>Work location (eg. HHS or town)</i>
Kate McLean	2024	MBBS, FRANZCR	Diagnostic Radiologist, PAH	RANZCR member, ARGANZ Liver group Lead, Diagnostic radiologist, Director of Training Multiple published journal articles, conference presentations	MSHHS
Dancia Cossio	2024	HIM	Senior Director, Cancer Alliance Queensland, MSHHS	Over 20 years' experience managing cancer information. Data custodian of QCR and QOR. Current Chairperson of the Australian Assoc of Cancer Registries. Development of innovative applications and solutions to support the collection of clinical information. Multiple published journal articles, conference presentations	CAQ, MSHHS

Privacy policy

The Cancer Alliance Queensland has access to a vast array of Queensland's public and private health related data, including population based cancer diagnoses, pathology, radiology, staging, death certificate, clinical and administrative cancer data systems.

About this privacy policy

This privacy policy applies to personal, sensitive and confidential information we collect, hold, use, disclose or you provide to us and how we comply with privacy obligations¹.

What is personal information?

Personal information is defined by the Information Privacy Act 2009. Put simply, it is information that identifies a living person (or could lead to them being identified).

What is sensitive information?

Sensitive information is a subset of personal information. Sensitive information includes health information and other information such as race, ethnicity, religious beliefs, sexual preferences or practices and criminal records. We take additional care in our collection and handling of sensitive information.

What is confidential information?

Confidential information is information about a person who is receiving or has received a public health service. Confidential information includes care and treatment information.

Unlike personal information, which is only about a living person, confidential information can be about a living or deceased person.

Queensland laws set out requirements for how we handle confidential information.

These laws include:

- *Hospital and Health Boards Act 2011 (HHBA)*
- *Public Health Act 2005 (PHA)*
- *Information Privacy Act 2009 (IPA)*

For the purpose of this policy personal, sensitive and confidential information will be referred to as confidential information.

How we use confidential information?

The Cancer Alliance Queensland collects and discloses health related information specifically for our programs of work. We also collect some personal information when people use our applications and website to improve our products and services.

Why we collect confidential information?

Statistics and information

We collect this information for a variety of reasons, including to:

- conduct analysis and report cancer information
- to improve the safety and quality of cancer services
- to enable the evaluation, management, monitoring or planning of cancer services
- undertake data linkage and integration
- support clinical and health service research
- develop and improve cancer statistics
- to provide clinicians with data systems and tools to enable the collection of clinical data

Other purposes

We may also collect confidential information for other purposes. This includes:

- users of our applications and website
- members or relevant persons of Cancer Alliance Queensland committees and working groups
- to distribute publications and communicate

How we collect confidential information?

We collect this information:

- directly from clinical and treatment systems, Queensland Cancer Register, Multidisciplinary teams via QOOL applications and the Department of Health
- indirectly from health administration sources, research projects, national death index

This information is collected in various ways including:

- paper based and electronic forms
- electronic data files
- emails or Microsoft teams
- our applications and website

Types of confidential information we hold

We may collect the following types of information as we perform our work:

- name, address and contact details
- demographics
- public and private health care facilities and providers of oncology services

We also collect and hold some sensitive information, including:

- health information
- race or ethnic origin
- people under the age 18yrs

How we secure and dispose of confidential information

The Cancer Alliance Queensland implements security measures following the Department of Health policies and procedures¹ to prevent accidental loss and from unauthorised access, use, alteration and disclosure.

We apply correct storage, handling and disposal methods so information has security classifications applied to them and are protected from unauthorised.

Electronic and paper records containing personal information are stored and protected in accordance with [Queensland Health information Security Policy Framework](#).

We support these broader requirements with many internal policies and procedures on:

- information security and privacy
- data custody

- submissions to HREC for projects involving personal information
- access to information
- data linkage
- de-identifying data
- release of statistical information

All our staff, contractors, medical students and visiting research officers must sign confidentiality agreements before they can access any data we hold. We only grant users with access to systems/information relevant to what they need to perform their work.

How we use and disclosure of confidential information

We only use this information to perform our work under the HHBA Act 2011 and PHA 2005 or in our capacity as an employer.

If we disclose confidential information, we do so as permitted by the HHBA Act 2011, PHA 2005 or IP Act to the following:

- disclosure for research
- other general disclosure
- State and Territory/Commonwealth entities
- other third parties such as authorised health care professionals

We may disclose personal information where:

- the person has consented
- the person would reasonably expect, or have been told, that we usually disclose information in a particular circumstance or to a particular person or organisation
- it is required or authorised by law

When will we seek consent to disclose confidential information?

We will not use or disclose this information without consent unless:

- it is disclosed or used for the purpose related to the primary purposes of collection detail and you would reasonably expect your personal information to be used or disclosed for such a purpose

- if we reasonably believe that the use or disclosure is necessary to lessen or prevent a serious or imminent threat to an individual's life, health or safety or to lessen or prevent a threat to public health or safety
- if we have reason to suspect that unlawful activity has been, or is being engaged in; or
- if it is required or authorised by law

We may obtain consent from an individual directly and if so it will be required in writing. In order for the consent to be valid you must be provided enough information to understand:

- the type of personal information being disclosed
- the purpose of the disclosure
- who will be receiving the information and what it will be used for by the recipient/s
- foreseeable consequences of agreeing to the disclosure

Do we transfer or disclose confidential information outside of Queensland?

From time to time, we may disclose health information, to individuals and organisations who are located outside of Queensland.

The kinds of individuals and organisations to whom we may securely transfer/disclose information outside of Queensland include third parties such as the Australian Institute of Health and Welfare or Universities conducting approved research studies. We may also disclose non identifiable information to researchers or international cancer entities in other countries.

Our applications, website and social media

When a user browses our website, we collect this information about their visit, which we use for statistical purposes:

- server or IP address
- date and time of visit
- pages accessed and documents downloaded
- search terms used
- type of browser used

When a user registers for an account for access to our application, we collect the following information about the user for approving access, auditing and monitoring purposes:

- personal information disclosed when registering for an account
- date and time of login
- pages accessed and edited

How to complain about a possible breach of privacy

We are committed to protecting your privacy. You can make a complaint if you believe we may have breached your privacy or our privacy obligations.

Send your complaint to the Senior Director of the Cancer Alliance Queensland providing your contact details.

We take all complaints seriously and are committed to quickly and fairly resolving them. If the matter is complex and takes longer to investigate than we first expected, we will keep you informed on when you will receive a response.

If you are not satisfied that we have resolved your complaint you can request that the matter is escalated for review by the Department of Health, to the Office of the Information Commissioner (OIC) Queensland.

How to contact us about privacy

If you have any questions or comments regarding this privacy policy and our privacy practices please contact: Senior Director of the Cancer Alliance Queensland CancerAllianceQld@health.qld.gov.au

Updates and availability to this policy

This Privacy Policy may be reviewed and amended from time to time to reflect changes to our practices, policies, systems and legal obligations. Any changes to this Privacy Policy will take effect from the date of posting on our website.

Some information in this policy has been referenced from the [Queensland Health Privacy Policy](#)¹

Meeting dates

Quality Assurance committee	Date
QCCSQP meeting <i>Note: Only one meeting held in 2024 because the Partnership membership was refreshed</i>	09.03.2022 13.07.2022 16.11.2022 19.07.2023 26.08.2023 (Strategic planning workshop) 28.10.2023 (Strategic planning workshop) 11.09.2024
Subcommittees <i>Note: subcommittees are rotated on a yearly basis to manage resources</i>	
Gynaecological Joint Working Group	26.07.2023
Lung cancer	21.06.2022 21.04.2023 04.08.2023 23.02.2024
Non-melanoma skin cancer	31.07.2023 02.12.2024
Paediatric	18.10.2024
Radiation Oncology	18.03.2022 09.12.2022
Systemic therapy	07.05.2024
Youth cancer	23.05.2024

Appendices

Publications in 2022-2024 reporting period

The Partnership

Queensland Cancer Quality Index 2007-2021 (Nov 2023)

<https://cancerallianceqld.health.qld.gov.au/media/yy1fslel/queensland-cancer-quality-index-2007-2021.pdf>

Treating the 6 Most Common Cancers in Queensland – A report for Hospital and Health Services 2017-2021 (June 2024)

<https://cancerallianceqld.health.qld.gov.au/media/zkibwqq3/treating-the-6-most-common-cancers-in-queensland-2017-2021.pdf>

Treating people with cancer in Queensland and Victoria – National benchmarking starts here 2017-2021 (June 2024)

<https://cancerallianceqld.health.qld.gov.au/media/bfcflj11/treating-people-with-cancer-in-queensland-and-victoria-updated-20th-june.pdf>

Cancer Insights – A focus on Queensland's Aboriginal and Torres Strait Islander Communities 2012-2021 (June 2024)

<https://cancerallianceqld.health.qld.gov.au/media/zx0boluj/cancer-insights-a-focus-on-queensland-s-aboriginal-and-torres-strait-islander-communities-2012-2021-1st-edition.pdf>

Head and Neck subcommittee

Human papillomavirus associated oropharyngeal cancer now the common mucosal head and neck cancer in Queensland (March 2024)

<https://cancerallianceqld.health.qld.gov.au/media/yq3k4c5e/j-med-imag-rad-onc-2024-porceddu-human-papillomavirus-associated-oropharyngeal-cancer-now-the-most-common-mucosal.pdf>

Queensland Head and Neck Cancer Quality Index 2015-2019 (Jan 2022)

<https://cancerallianceqld.health.qld.gov.au/media/1986/queensland-hnc-quality-index-2015-2019.pdf>

Radiation Oncology subcommittee

Utility of 30-day mortality as a quality metric for palliative radiation treatment: A population-based analysis from Queensland, Australia (Feb 2024) <https://onlinelibrary.wiley.com/doi/10.1111/1754-9485.13633?af=R>

Radiation Oncology in Queensland: Indicators of safe, quality cancer care delivered by public and private services 2009-2018 (Apr 2022)

<https://cancerallianceqld.health.qld.gov.au/media/1992/radiation-oncology-in-qld-2009-2018.pdf>

Colorectal cancer subcommittee

Queensland Colon Cancer Quality Index: 2012-2021 (Nov 2023)

<https://cancerallianceqld.health.qld.gov.au/reports/colorectal2023website-colonreport2023/#tab1>

Queensland Rectal Cancer Quality Index: 2012-2021 (Nov 2023)

<https://cancerallianceqld.health.qld.gov.au/reports/colorectal2023website-rectalreport2023/#tab1>

A population-based study of the management of rectal malignant polyps and the use of trans-anal surgery (July 2022)

<https://cancerallianceqld.health.qld.gov.au/media/2008/anz-journal-of-surgery-a-population-based-study-of-the-management-of-rectal-malignant-polyps-and-the-use-of-trans-anal-surgery.pdf>

Melanoma subcommittee

Trends and patterns of care of sentinel node biopsy in cutaneous melanoma: a population-based study in Queensland (Mar 2023)

<https://onlinelibrary.wiley.com/doi/full/10.1111/ans.18372>

Brain subcommittee

Queensland Brain Cancer Quality Index 2011-2020 (Aug 2023)

<https://cancerallianceqld.health.qld.gov.au/reports/braincqi2023website-brainreport2023/#tab1>

Haematology subcommittee

Queensland Acute Myeloid Leukaemia Quality Index 2012-2021 (Jan 2024)

<https://cancerallianceqld.health.qld.gov.au/reports/aml2023website-amlreport2023/#tab1>

Lung cancer subcommittee

Queensland Non-small Cell Lung Cancer Quality Index 2012-2021 (Sept 2024)

<https://cancerallianceqld.health.qld.gov.au/reports/lung20122022website-lungreport20122021/#tab1>

Breast Cancer subcommittee

Development of a Key performance indicators for breast cancer in Queensland, Australia (Nov 22)

<https://cancerallianceqld.health.qld.gov.au/media/2033/development-of-a-key-performance-indicator-for-breast-cancer-in-in-queensland-australia.pdf>

Queensland Breast Cancer Quality Index 2010-2019 (June 2022)

<https://cancerallianceqld.health.qld.gov.au/reports/breastreport2022website-breastreport2022/#tab1>